Ligand validation:3SXC

GAL: beta-D-galactopyranose

GAL is a Ligand Of Interest in 3SXC designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3SXC_GAL_A_2	34%	56%	0.249	0.932	0.88	0.82	-	-	0	0	100%	1
4FRD_GAL_A_402	82%	46%	0.067	0.922	0.9	1.19	-	1	0	0	100%	0.8
4FRA_GAL_A_402	67%	25%	0.118	0.926	1.4	1.65	3	4	0	0	100%	0.6
3SXD_GAL_A_2	65%	55%	0.141	0.943	0.71	1.03	-	1	1	0	100%	1
3SX8_GAL_A_2	62%	24%	0.131	0.924	1.13	1.95	1	6	0	0	100%	1
4GBP_GAL_A_404	61%	47%	0.158	0.948	0.8	1.24	-	1	0	0	100%	0.8
4WWH_GAL_A_401	100%	64%	0.026	0.99	0.47	0.9	-	-	0	0	100%	1
5ELB_GAL_C_202	100%	58%	0.036	0.992	0.82	0.8	-	-	0	0	100%	0.6
3OGR_GAL_A_1024	99%	47%	0.053	0.987	0.79	1.26	-	1	1	0	100%	1
1NSX_GAL_B_2400	98%	50%	0.055	0.981	0.56	1.36	-	3	0	0	100%	1
5DVJ_GAL_B_501	98%	40%	0.047	0.968	0.95	1.38	-	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.